Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor on blood‑vessel walls, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dosage and administration schedule for Icatibant Fresenius are determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of the attack, and regulatory guidelines. The prescriber will specify the exact dose and timing.

Safety data for icatibant acetate in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women, and use it only if clearly needed.

To order Icatibant Fresenius, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Icatibant Fresenius is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant acts directly on the bradykinin pathway, offering rapid symptom relief after subcutaneous injection, while the alternatives work upstream or replace deficient proteins.

Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the solution, as these conditions can affect its stability and efficacy.

The medication is supplied as a sterile solution for injection and is administered subcutaneously, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of systemic angioedema unrelated to HAE. Patients should be observed after injection and instructed to seek immediate medical attention if they experience any signs of a severe allergic reaction.

Icatibant Fresenius should not be used by individuals with a known hypersensitivity to icatibant acetate or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or other agents that increase bradykinin levels, and it is generally avoided in unconfirmed diagnoses of HAE.